()


:
.

: ,
, .

:
.

:
( )

:
()

/:

:

3

, ,
,


( -placebo)

19
,
20
,
, , , ,

1950, ,



(Regulatory Affairs)
5

 (1)

.

- (Papaver somniferum),
- (Atropa bellantona),
- (Digitalis lanata).

- ,
- ,
- ()
- ,

:
-
- ( )
- -IFN ( )
6
- TPA ( )

 (2)

- (Fleming, Florey, Chain, Heatley)
-

()
(),

().
( -).
( ), ()- .

 (3)

( -)
:
-
* ( )
* ( )
- .
,

:
-
-
.
8

 (4)

- .
* - .
, , .
* - .
* - .

* - 2
. , .
- .
.
- - .

 (5)

-
-
* anti-VEGF (, )
* anti-TNF ( )
-
* ( , )

- ( )
,
.
10

 (6)


,



, ,
, (
60% )
: -

- (, )
11
- (, DNA- )


.
(
) :
- ( ,
, )
-
() ( ).

.

.
:
- -
- - .

12

13

14

Full
Development

Post-launch
Activities
Registration
Phase III Trials

Early
Development

Drug
Discovery

IND

Phase II Trials
PoC/Phase I Trials
Early Clinical Safety and Efficacy in
Primate Disease Models
Lead Optimization, Pharmacology and
Efficacy in Animal Disease Models
Hit Finding and Validation
Target Identification and Validation
15

 (1)
in vitro in vivo .
:

16


.
- (-)
- (FDA, USA)
- (CSM, UK)
- ()

17

 ,
( ) -

IND (Investigational New Drug) :

.
18

 (1)
( )
-
-
-
-
-
.
:
-
-
-
-
24-30
19

 (2)
( )
-
.
- (- ) .
-

- .
12-24

20

 (3)
( )
-
-
- -
-
- (,
).
-
.
14-24 .

21

 (4)
. ( V)
-

(. , )
.

22


( )
Notice to the applicants
1996

- ,
.

-- ( )
23


,
.


()

20

(me too drugs)

(generics)


-

24





(.1729/87)

:
(. N-(4hydroxyphenyl)acetamide
(. )
(. DEPON)-
(. PANADOL)
25


;
,

26


A,


,

.

27


-
* (per os)
* (,
, )
*

-
-
-
* (SC)
* (IM)
* (IV)
-
28


- (# )
- (, , )

(, per
os, , , , SC, IM, IV)

IV special
-
-

29

30

 (1)

31

 (2)






-

32

 (3)


:

33

 (4)

:

()


34

35

 (1)

36

 (2)

:



.

37

100 ( )

75 100

75 100

5 <100

30 <100

5 <100

80 100

38




(Cmax)

(Tmax)

Cmax

(3)

Cmax

Tmax

39

 (4)

(AUC)

AUC

( )




(AUCperos)

(AUCIV)

40

(/)



Cmax

20%

AUC,

Cmax Tmax
41

 (1)



( )

-

(/)

42

 (2)




,

43

 (3)

44

 (Vd)
( )
,

(~4L)
(~14L)
(~28L)

45

-
-
-

( ,
, .)
46






,
,
,


,
. ,
,



47



( )
( )

48

 1
1
1


(. 40-70%

)

,

,

49

 (1)

-
,
(
)


( )
50

- 450 (CYP3A4, CYP2C19)-

51
- -

 (2)

- :

52


(1)
-


.
(,
)

53

(
)

CES2

54



,

+, +-ATPase

55

Cmax

Tmax

,
56

 ( )
(t1/2)

0.7 x Vd

t1/2=

ln(2)

CL

57

(%)

50

50

50+25

75

50+25+12,5

87,5

50+25+12,5+6,25

93,8

50+25+12,5+6,25+3,12
5

96,9

93%
4 t 1/2

58

 (1)
( )
:

.


.

.

59


24
.

-
(Target
concentration)
.

(maintenance dose)
-
(steady-state) .

(dosing rate)
(dosing intervals)
(loading dose)

.
60

 (2)
( )

(target concentration)

( ,
61
)

 (3)
-

,
-

.
-
4-5
-

.
62

(t1/2=4h)

0,5

1,5

0,75

1,75

0,88

12

1,88

0,94

16

1,94

0,97

20

1,97

0,99

24

1,99

63

 (4)

():

():



,
,
() (),

():
-
.


.

64
.

(t1/2=4h)

1,5

3,5

1,75

12

3,75

1,88

16

3,88

1,94

20

3,94

1,97

24

3,97

. 7 .
4 94%
(steady state)

65

,
.
66

 (1)



-,





67






, , .

68


- (1)

(
)
(
)

(
)

69


- (2)

(ED50)

(TD50)

(LD50)

(LD50/ED50)

70

(.

)



(. )
71


(1)
:
- ()

:

72


(2)
:

-,

. ,


-

73